Stryker Co. (NYSE:SYK) Shares Sold by Everett Harris & Co. CA

Everett Harris & Co. CA cut its stake in shares of Stryker Co. (NYSE:SYKFree Report) by 2.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,297 shares of the medical technology company’s stock after selling 168 shares during the period. Everett Harris & Co. CA’s holdings in Stryker were worth $2,267,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Zhang Financial LLC lifted its stake in Stryker by 55.0% during the fourth quarter. Zhang Financial LLC now owns 114,889 shares of the medical technology company’s stock worth $41,366,000 after purchasing an additional 40,784 shares in the last quarter. Dale Q Rice Investment Management Ltd purchased a new position in Stryker during the 4th quarter valued at about $587,000. Berkshire Bank increased its stake in Stryker by 13.8% during the fourth quarter. Berkshire Bank now owns 8,489 shares of the medical technology company’s stock worth $3,056,000 after purchasing an additional 1,030 shares during the period. PFW Advisors LLC acquired a new stake in shares of Stryker during the fourth quarter worth about $1,350,000. Finally, Traynor Capital Management Inc. purchased a new position in shares of Stryker in the fourth quarter valued at approximately $324,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Stryker

In related news, CEO Kevin Lobo sold 57,313 shares of the business’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the transaction, the chief executive officer now owns 100,027 shares of the company’s stock, valued at approximately $36,879,954.90. The trade was a 36.43 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 5.90% of the stock is currently owned by insiders.

Analyst Ratings Changes

SYK has been the subject of several recent research reports. The Goldman Sachs Group raised their price target on shares of Stryker from $384.00 to $427.00 and gave the company a “neutral” rating in a research report on Thursday. Piper Sandler reissued an “overweight” rating and issued a $420.00 target price (up previously from $380.00) on shares of Stryker in a report on Wednesday, October 30th. Evercore ISI lifted their price target on Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Truist Financial raised their target price on Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a research report on Thursday. Finally, Citigroup increased their price target on shares of Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Five analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $419.37.

Read Our Latest Stock Report on Stryker

Stryker Stock Up 0.1 %

SYK stock opened at $390.90 on Friday. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. The company has a market cap of $149.02 billion, a P/E ratio of 50.37, a P/E/G ratio of 2.68 and a beta of 0.95. The company’s 50-day moving average price is $376.56 and its 200 day moving average price is $362.38.

Stryker (NYSE:SYKGet Free Report) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.86% and a net margin of 13.25%. During the same period in the previous year, the company posted $3.46 EPS. On average, research analysts expect that Stryker Co. will post 13.53 earnings per share for the current fiscal year.

Stryker Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Tuesday, December 31st were given a $0.84 dividend. The ex-dividend date was Tuesday, December 31st. This is a positive change from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 annualized dividend and a dividend yield of 0.86%. Stryker’s payout ratio is currently 43.30%.

Stryker Company Profile

(Free Report)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

See Also

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYKFree Report).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.